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Clinical Question 
How do you monitor patients with Alzheimer's disease to determine if they are benefiting from 
receiving a cholinesterase inhibitor? 
Evidence-Based Answer 
Patients with Alzheimer's disease who undergo treatment of any kind should be monitored eight 
weeks after initiation of therapy and at least every six months thereafter. (Strength of 
Recommendation: C, based on expert opinion and extrapolation from drug effectiveness studies) 
There are no clinical trials directly assessing the best way to monitor patients on a cholinesterase 
inhibitor. The Alzheimer's Disease Assessment Scale for Cognition (ADAS-Cog) and the 
Clinician Interview-Based Impression of Change Scale plus Caregiver Input (CIBICS-CI) are the 
most commonly used instruments to establish effectiveness of Alzheimer's medications in 
clinical trials; however, these tools are lengthy and cumbersome to use. The Mini-Mental State 
Examination (MMSE) also has been used in clinical trials of cholinesterase inhibitors, and 
although it is familiar to most physicians, it lacks specificity. 
Evidence Summary 
For a new Alzheimer's disease medication to receive U.S. Food and Drug Administration 
approval, clinical trials must show that it improves cognitive and global function according to a 
validated assessment scale.1 The ADAS-Cog, which evaluates language, orientation, motor skills 
(praxis), and memory, is the standard instrument for measuring cognitive function in clinical 
trials.2 It represents one of two subsets of the Alzheimer's Disease Assessment Scale. The 
maximal score possible is 70, with worsening dementia resulting in a higher score. 
Unfortunately, the ADAS-Cog is not an ideal test for use by primary care physicians because it 
requires training to administer it, and the test can take 30 to 45 minutes to complete.3 
Untreated patients with Alzheimer's disease show a statistically significant increase of four to six 
points over 12 months on the ADAS-Cog, and persons without Alzheimer's disease show no 
significant change.2,4 Over the first six to 12 months, patients treated with cholinesterase 
inhibitors showed improvement by an average of 2.7 points.5 However, literature suggests that 
30 to 50 percent of patients may not respond to treatment at all, and 20 percent may have better-
than-average improvement.6 
The CIBICS-CI is the assessment tool most commonly used to determine global functional 
change in drug trials.2,7 The Alzheimer's Disease Cooperative Study created a standardized 
version of this test, which consists of semi-structured interviews of the patient and a caregiver 
followed by an evaluation of change on a seven-point scale. 
In one prospective trial, the CIBICS-CI was found to have good short-term reliability, with 94 
percent of patients with Alzheimer's disease showing little or no change at one month. It was 
validated as demonstrating significant global decline in patients with Alzheimer's disease (56 
percent of patients at six months and 81 percent at 12 months) and no significant change in 
patients in a control group over the same period.8 Most physicians are not familiar with the 
CIBICS-CI, and the interviews typically take a minimum of 40 minutes to perform. 
Although initially designed as a screening tool, many clinical trials have used the MMSE as a 
secondary measure of cognitive function because most physicians are familiar with it and 
because it is easy to administer, usually taking 5 to 10 minutes to complete. The MMSE consists 
of 30 items that evaluate orientation, memory, attention, language, and motor skills. 
Untreated patients with Alzheimer's disease usually decline two to four points per year on the 
MMSE.2 The MMSE shows good internal consistency and good test-retest reliability. Most 
studies reveal the MMSE has a sensitivity and specificity between 80 to 100 percent in detecting 
dementia9,10; however, it has increased variability compared with the ADAS-Cog and is not 
considered specific enough to be used alone to evaluate treatment response.2,5 The MMSE also 
becomes less sensitive to progressive decline as the lower limits of the scale are approached.10 
Of the many assessment tools validated for use in patients with Alzheimer's disease, there are 
several that demonstrate the effectiveness of cholinesterase inhibitors versus placebo in 
randomized controlled trials (Table 111,12). Other scales that have the potential to be useful 
include the Instrumental Activities of Daily Living Scale, Geriatric Depression Scale, and 
Caregiver Burden Scale.12 
Table 1. Tools Detecting Positive Outcomes in Patients with Alzheimer's Disease on 
Cholinesterase Inhibitors 
Measurement Tool 
Cognitive function Alzheimer's Disease Assessment Scale for Cognition; Mini-
Mental State Examination* 
Clinical Global 
Impression or Global 
Disease Severity 
Clinical Dementia Rating Scale†; Clinician Interview-Based 
Impression of Change Scale plus Caregiver Input; Gottfries, 
Brane and Steen Scale†; Mental Function Impairment Scale† 
Activities of daily Caregiver-rated Modified Crichton Scale†; Disability 
living Assessment for Dementia; Progressive Deterioration Scale; 
Instrumental Activities of Daily Living Scale*†; Physical 
Self-Maintenance Scale† 
Behavioral 
disturbances or quality-
of-life 
Neuropsychiatric Inventory Questionnaire* 
 
*- Recommended by the American Family Physician review article. 
†- Used in donepezil (Aricept) trials only. 
Information from references 11 and 12 
Recommendations from Others 
No subspecialty group guidelines give concrete recommendations regarding how monitoring 
should be done or which tools should be used. The Alzheimer's Association suggests 
postdiagnostic monitoring of patients every six months or any time there is a behavioral change 
or sudden decline in function.13 
Clinical Commentary 
Monitoring the clinical effect of a cholinesterase inhibitor is difficult because of the varying 
symptoms and rate of decline among patients with Alzheimer's disease. The CIBICS-CI and 
other global function scales were designed to measure clinically meaningful and distinct 
changes2; however, these scales are cumbersome to administer in the outpatient setting. 
Assessment of meaningful change could perhaps be tailored to each patient by using shorter tests 
or clinical interview questions that document improvement or stability in the one or more 
domains most troublesome to a specific patient and his or her family. 
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